D-塔格糖(D-tagatose) - 在研适应症：普拉德-威利综合症，2型糖尿病，I型高脂蛋白血症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(3S,4S,5R)-1,3,4,5,6-pentahydroxyhexan-2-one、D-lyxo-hex-2-ulose、D-lyxo-hexulose

+ [4]

靶点-

作用机制

铁螯合剂

治疗领域

神经系统疾病遗传病与畸形内分泌与代谢疾病+ [1]

在研适应症

普拉德-威利综合症2型糖尿病I型高脂蛋白血症

非在研适应症-

原研机构

Chromadex Corp.

在研机构

Biospherics.net, Inc.Chromadex Corp.

非在研机构

Dominari Holdings, Inc.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C6H12O6

InChIKeyBJHIKXHVCXFQLS-PQLUHFTBSA-N

CAS号87-81-0

关联

5

项与 D-塔格糖相关的临床试验

NCT06230900

/ Active, not recruitingN/AIIT

Assessment of Mass Balance of Orally Administered [14C] (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one in Healthy Volunteers Using a Microtracer Approach

Worldwide almost 40% of the adult population is overweight (including >10% obese), and more than 350 million children (up to the age of 19) are overweight. Overweight and obesity are significant problems and important risk factors for several lifestyle-related diseases, such as cardiovascular disease, certain cancers, non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D). Excessive consumption of glucose/sucrose is a major contributor to overweight and obesity. Alternative, low-calorie sweeteners could reduce daily energy intake and thus slow down the development of these conditions and related diseases. (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one is a sweetener that may be suitable for use as a sugar substitute; it is only partially digested in the small intestine and as a result has a lower energy density than more traditional sweeteners such as sucrose. However, it is not yet known to what extent (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one is used in the body and then excreted.
The aim of this study is to measure the metabolic utilization (the 'mass balance') of a single dose of 14C-labelled (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one and AMS technology. Based on clinical data of excretion (urine and faeces) and CO2 production (expired air), the mass balance can be derived. These generated results will be used to map the metabolic pathways (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one undergoes during the digestion process. In addition, it will provide insight into the use of AMS technology to investigate the relationship between diet and health.

开始日期2024-02-05

申办/合作机构

Wageningen University

[+2]

JPRN-UMIN000026233

/ CompletedN/AIIT

A study of the effects on oral bacteria with D-Tagatose chewing gum - A study with D-Tagatose chewing gum

开始日期2015-08-06

申办/合作机构-

NCT00961662

/ Completed临床2期

Dose Ranging Effects of Three Low-doses of Naturlose™ (Tagatose) on Glycemic Control and Safety of Naturlose™ (Tagatose) Over Six Months in Subjects With Mild Type 2 Diabetes Mellitus Under Control With Diet and Exercise.

This study is a six-month, prospective, randomized, multicenter, single- blind, controlled clinical study to evaluate the effect of three low-doses of Naturlose (Tagatose) on glycemic control and safety in subjects with Type 2 diabetes under diet control and exercise. The subjects were randomized in one of the 3 arms receiving 2.5, 5 or 7.5 gm of Tagatose.

开始日期2008-02-01

申办/合作机构

University of Kentucky

100 项与 D-塔格糖相关的临床结果

登录后查看更多信息

100 项与 D-塔格糖相关的转化医学

登录后查看更多信息

100 项与 D-塔格糖相关的专利（医药）

登录后查看更多信息

877

项与 D-塔格糖相关的文献（医药）

2025-01-15·Journal of Agricultural and Food Chemistry

Thermostability Enhancement of Tagatose 4-Epimerase through Protein Engineering and Whole-Cell Immobilization

Article

作者: Guo, Xuehong ; Liu, Zhanzhi ; Wu, Jing ; Xu, Ying

d-Tagatose, a rare sugar endowed with a low-calorie property, superior taste quality, and probiotic functionality, has garnered significant research attention. However, the prevailing biological production methods relying on β-galactosidase and l-arabinose isomerase face challenges including high cost and suboptimal conversion efficiency. Consequently, it is of great research significance to find efficient alternative routes for d-tagatose synthesis. Previously, Thermotoga petrophila tagaturonate 3-epimerase was modified to function as tagatose 4-epimerase (T4E) enabling the direct conversion of d-fructose to d-tagatose. In this study, T4E was further engineered through directed evolution, specifically targeting the enhancement of its thermostability for application. This endeavor yielded promising T4E variants with superiority over those of the original enzyme. T4E I430P exhibits a half-life (t_1/2) at 70 °C that is 1.83-fold that of T4E, with an increased melting temperature (T_m) of 5.1 °C compared to T4E. Additionally, T4E G90S/T272A/I430P demonstrated a 21.4% increase in specific activity compared to T4E. At 70 °C, its t_1/2 was 1.69-fold that of T4E, and its T_m is 2.9 °C higher than T4E. Furthermore, whole-cell immobilization integrating these engineered T4E variants into a robust biocatalytic system was employed. This innovative approach not only underscores the practical feasibility of modifying enzymes through directed evolution but also establishes a foundation for the cost-effective, large-scale production of d-tagatose.

2025-01-01·Radiotherapy and Oncology

EGCG protects intestines of mice and pelvic cancer patients against radiation injury via the gut microbiota/D-tagatose/AMPK axis

Article

作者: Li, Ming ; Yang, Yinyin ; Li, Mingyue ; Tang, Fengling ; Wang, Difan ; Liu, Chengzhi ; Xie, Liwei ; Gu, Xuhao ; Tian, Ye ; Zhu, Ruiqiu ; Lu, Haiyan ; Guo, Liangsheng ; Cai, Shang

BACKGROUND AND PURPOSERadiation-induced intestinal injury (RIII) compromises the clinical utility of pelvic radiotherapy (RT). We aimed to explore the protective effect and underlying mechanism of (-)-epigallocatechin-3-gallate (EGCG) on RIII.MATERIALS AND METHODSWe evaluated the protective effect of EGCG on intestine in RIII mouse model and pelvic cancer patients, while explored the underlying mechanism through (1) 16S rRNA sequencing, (2) metabolomic profiles, (3) fresh sterile fecal filtrate (SFF) transplantation, and (4) transcriptome sequencing.RESULTSEGCG efficiently prevented RIII in mouse, as reflected by improved survival, alleviated intestinal structure damage, promoted intestinal regeneration, and ameliorated gut microbiota dysbiosis. Prophylactic EGCG intervention reduced the severity of RIII in patients receiving pelvic RT. Mechanistically, the protective effect of EGCG could be transferred to other mice by SFF transplantation. EGCG enriched gut microbiota-derived metabolite D-tagatose, and oral administration of D-tagatose reproduced the radio-protective effect of EGCG via activating AMPK.CONCLUSIONOral EGCG may be a promising strategy for preventing RIII clinically, and warrant further investigation in prospective randomized phase III trials.

2025-01-01·Applied Biochemistry and Biotechnology

Development and Characterization of a Tunable Metal–Organic Framework (MOF) for the Synthesis of a Rare Sugar D-Tagatose

Article

作者: Mittal, Divya ; Bhatiya, Simran ; Dhiman, Rishu ; Yadav, Sudesh Kumar ; Rai, Shushil Kumar

D-tagatose is a valuable rare sugar with potential health benefits such as antiobesity, low-calorie, prebiotic, and anticancer. However, its production is mainly depending on chemical or enzymatic catalysis. Herein, a cobalt-based metal-organic framework (MOF) was developed at room temperature in an aqueous system using a self-assembly method. The L-arabinose isomerase (L-AI) was immobilized into this unique MOF by an in situ encapsulation process. The morphology and structural aspects of the MOF preparations were characterized by different analytical techniques such as scanning electron microscopy (SEM), energy dispersive X-ray spectroscopy (EDX), confocal laser scanning microscopy (CLSM), Fourier transform infrared spectroscopy (FT-IR), and X-Ray diffraction (XRD). Moreover, thermogravimetric analysis (TGA) suggested the high thermal stability of the L-AI@MOF. Significantly, the immobilized catalyst exhibited enhanced catalytic efficiency (k_cat/K_m) of 3.22 mM^-1 s^-1 and improved turnover number (k_cat) of 57.32 s^-1. The L-AI@MOF efficiently catalyzes the synthesis of D-tagatose from D-galactose up to the equilibrium level (~ 50%) of isomerization in heterogeneous catalysis. Interestingly, L-AI@MOF was found stable and reusable for more than five cycles without the requirement of additional metal ions during catalysis. Thus, L-AI stabilized in the MOF system demonstrated a higher catalytic activity and potential guidance for the sustainable synthesis of rare sugar D-tagatose.

100 项与 D-塔格糖相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	D-塔格糖	-	DB04936

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型糖尿病	临床3期	-	Chromadex Corp.	-
I型高脂蛋白血症	临床3期	-	Chromadex Corp.	-
普拉德-威利综合症	临床3期	-	Chromadex Corp.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00955747 (NEET, CTgov)	临床3期	2型糖尿病	494	Sugar Substitute Splenda (Sugar Substitute Splenda)	鹹廠製膚鏇簾窪鹽蓋鹽(襯齋壓繭蓋蓋簾鹹襯觸) = 衊膚窪鏇糧廠構選鬱憲壓鏇齋構鹹構憲壓製顧 (顧積壓築壓衊鹽製艱憲, 鹽繭構廠衊顧憲遞範鏇 ~ 鑰繭構憲壓遞顧齋鹽廠) 更多	-	2014-11-19
				Tagatose (Tagatose)	鹹廠製膚鏇簾窪鹽蓋鹽(襯齋壓繭蓋蓋簾鹹襯觸) = 選襯選鏇網膚憲網選鹽壓鏇齋構鹹構憲壓製顧 (顧積壓築壓衊鹽製艱憲, 齋構製願蓋鑰網構積鹽 ~ 願齋築鏇膚艱淵繭積壓) 更多
NCT00961662 (CTgov)	临床2期	2型糖尿病	161	D-Tagatose (2.5 Active)	觸獵觸鹽糧壓蓋願簾觸(廠積範製醖憲選憲築觸) = 艱艱獵簾夢顧鏇淵餘衊膚選願顧觸鬱範齋餘衊 (衊艱網範鏇窪鑰糧構醖, 鬱壓積餘鏇鏇範醖鬱憲 ~ 醖廠廠齋鏇艱憲廠遞廠) 更多	-	2014-11-06
				D-Tagatose (5.0 Mid Dose)	觸獵觸鹽糧壓蓋願簾觸(廠積範製醖憲選憲築觸) = 窪築艱獵獵觸壓顧繭糧膚選願顧觸鬱範齋餘衊 (衊艱網範鏇窪鑰糧構醖, 夢鑰糧艱選願憲構獵壓 ~ 製淵鏇繭鹽鹽膚築積獵) 更多